350 Epizód

  1. 346: Zealand's obesity strategy and Immunovant's curious development plan

    Közzétéve: 2025. 03. 20.

  2. 345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

    Közzétéve: 2025. 03. 13.

  3. 344: Trump's FDA commissioner nominee takes the hot seat

    Közzétéve: 2025. 03. 06.

  4. 343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

    Közzétéve: 2025. 02. 27.

  5. 342: FDA cuts, zombie biotechs, and too much weight loss?

    Közzétéve: 2025. 02. 20.

  6. 341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

    Közzétéve: 2025. 02. 13.

  7. 340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

    Közzétéve: 2025. 02. 06.

  8. 339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

    Közzétéve: 2025. 01. 30.

  9. 338: Chinese biotechs, a WHO departure, and post-JPM thoughts

    Közzétéve: 2025. 01. 23.

  10. 337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

    Közzétéve: 2025. 01. 15.

  11. 336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

    Közzétéve: 2025. 01. 09.

  12. 335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

    Közzétéve: 2024. 12. 19.

  13. 334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

    Közzétéve: 2024. 12. 12.

  14. 333: An H5N1 bird flu update and talent scarcity in the radiopharma field

    Közzétéve: 2024. 12. 05.

  15. 332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

    Közzétéve: 2024. 11. 21.

  16. 331: AbbVie’s stumble, Amgen’s tumble and more election fallout

    Közzétéve: 2024. 11. 14.

  17. 330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

    Közzétéve: 2024. 11. 07.

  18. 329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

    Közzétéve: 2024. 10. 31.

  19. 328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

    Közzétéve: 2024. 10. 24.

  20. 327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

    Közzétéve: 2024. 10. 17.

1 / 18

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Visit the podcast's native language site